

# Balaxi Pharmaceuticals Limited

To  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C/1, G Block, BKC  
Bandra (E), Mumbai-400051

19<sup>th</sup> January, 2021

**Stock Code: BALAXI**

**Sub: Outcome of the Board Meeting**

Dear Sir/Madam,

With reference to the above subject, we wish to inform you that the Board of Directors at their meeting held on 19<sup>th</sup> January, 2021, inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and nine-months ended on 31<sup>st</sup> December, 2020. The said financial results along with the Limited review Report is enclosed herewith.

The board meeting commenced at 11:00 AM and concluded at 2:05 PM

The above information is available at the website of the Company at [www.balaxipharma.in](http://www.balaxipharma.in)

This is for your information and record.

Thanking You

Yours Faithfully,

For Balaxi Pharmaceuticals Limited



Chinta Shalini  
Company Secretary



**Registered Office:**

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

(Formerly known as Balaxi Ventures Limited)

# Balaxi Pharmaceuticals Limited

## Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2020

Particulars	(Rs. in Lakhs)					
	Quarter Ended			Nine Months Ended		Year ended
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Income</b>						
Revenue from operations	2,091.19	2,220.94	1,314.30	6,427.40	3,392.41	4,563.24
Other income	(22.00)	51.90	69.85	176.66	164.10	59.49
<b>Total Income</b>	<b>2,069.20</b>	<b>2,272.84</b>	<b>1,384.14</b>	<b>6,604.07</b>	<b>3,556.51</b>	<b>4,622.73</b>
<b>Expenses</b>						
Cost of materials consumed	1,527.49	1,609.14	872.31	4,679.93	2,498.54	3,285.14
Employee benefit expense	50.14	48.30	48.83	138.11	131.74	176.21
Finance cost	-	-	-	-	-	-
Depreciation and amortisation expense	2.59	3.03	0.17	6.33	0.42	0.75
Other expenses	83.32	43.36	116.80	176.01	278.62	234.07
<b>Total Expenses</b>	<b>1,663.54</b>	<b>1,703.83</b>	<b>1,038.11</b>	<b>5,000.38</b>	<b>2,909.32</b>	<b>3,696.18</b>
<b>Profit/(loss) before tax and other comprehensive income</b>	<b>405.66</b>	<b>569.01</b>	<b>346.03</b>	<b>1,603.69</b>	<b>647.20</b>	<b>926.55</b>
<b>Tax expenses</b>						
Current tax	105.36	142.79	98.50	405.98	182.28	276.64
Deferred tax	(0.08)	(0.10)	0.15	0.32	0.32	0.34
<b>Net Profit/(loss) for the period</b>	<b>300.37</b>	<b>426.32</b>	<b>247.39</b>	<b>1,197.38</b>	<b>464.60</b>	<b>649.57</b>
<b>Other comprehensive income</b>						
A (i) Items that will not be reclassified to profit or loss in subsequent period	-	-	-	-	-	-
Re-measured gains on defined benefit plans	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total comprehensive income for the year</b>	<b>300.37</b>	<b>426.32</b>	<b>247.39</b>	<b>1,197.38</b>	<b>464.60</b>	<b>649.57</b>
Paid up equity share capital - Face value of Rs.10 each	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Other Equity						
<b>Earnings Per Share (EPS)</b>						
(EPS for the quarter is not annualised)						
-Basic (Amount in Rs.)	3.00	4.26	2.47	11.97	4.65	8.64
-Diluted (Amount in Rs.)	3.00	4.26	2.47	11.97	4.65	8.64

1. The name of the company was officially changed to Balaxi Pharmaceuticals Limited w.e.f 7th October 2020

2. The Unaudited Standalone Financial Results for the quarter ended December 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 19, 2021 and have been subjected to Limited Review by the Statutory Auditors of the Company. The Standalone Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act,

3. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.

For and on behalf of Board of Directors,

*Minoshi Maheshwari*

Minoshi Maheshwari  
Director  
DIN: 01575975



Place: Hyderabad

Date: 19 January 2021

### Registered Office:

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors  
Balaxi Pharmaceuticals Limited  
(Formerly Known as Balaxi Ventures Limited)**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of BALAXI PHARMACEUTICALS LIMITED (Formerly Known as Balaxi Ventures Limited) ("the Company") for the quarter and nine months ended 31<sup>st</sup> December 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019
2. The preparation of "the Statement", which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We have conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.,  
Chartered Accountants  
FRN: 007257S

}

m



P. Murali Mohana Rao  
Partner

M.No. 023412

UDIN: 21023412AAAADX2006

Place: Hyderabad  
Date: 19-01-2021.

